Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

No significant differences were observed in ageing‐related biomarkers (IGF‐1, vitamin D) or most inflammatory markers, except for a trend towards higher hsCRP levels (Table S5).

Source: Association of Muscle‐Specific Strength With Biomarkers. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I‐Lan Longitudinal Aging Study.

Source: Abstract.

Participants were categorized into low and normal MSS groups using age‐sex‐specific cutoffs based on quintiles.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Cohort study · Journal of Cachexia, Sarcopenia and Muscle · 2025

Original publication title

Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Wen‐Kai Chien; Wei‐Ju Lee; Chih‐Kuang Liang; Ko‐Han Yen; Li‐Ning Peng; Ming‐Hsien Lin; Ching‐Hui Loh; Fei‐Yuan Hsiao; Liang‐Kung Chen

© 2025 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Sarcopenia, characterized by the age‐related progressive loss of muscle mass and function, significantly increases the risk of impaired physical performance, disability, reduced quality of life and mortality among older adults [1, 2]. Previously, sarcopenia assessment has relied on separate measurements of muscle mass or function [3]. Yet, taken alone, these indicators often fall short in capturing overall muscle function. Therefore, current consensus definitions of sarcopenia, including those from the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS 2019), emphasize combined muscle mass, muscle strength and physical performance as the diagnostic components [4, 5].

Recently, the Global Leadership Initiative on Sarcopenia (GLIS) has proposed a new diagnostic algorithm for sarcopenia that designates muscle strength or muscle‐specific strength (MSS) as the primary metric for assessing muscle function, while reclassifying physical performance parameters as outcome indicators of sarcopenic progression [6].

In addition to muscle strength, some researchers use the Muscle Quality Index (MQI): grip strength divided by total appendicular lean mass: as a marker of muscle efficiency [7, 8]. However, MQI has inherent limitations related to sex‐specific differences in muscle distribution and potential misclassification due to differences in body composition. Men typically carry relatively more muscle mass in the upper body, whereas women have a higher proportion of lean mass concentrated in the lower limbs [9]. Moreover, when grip strength is normalized to total lean mass, obese individuals may appear to have artificially low MQI values due to high leg mass inflating the denominator, despite having adequate upper limb strength.

MSS, defined as grip strength normalized specifically to upper limb lean mass, reduces the biases derived from MQI. Despite the potential utility of MSS in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia‐related outcomes remain scarce, particularly among Asian populations, thus limiting the clinical application of MSS as a diagnostic criterion for sarcopenia. This current study aimed to evaluate MSS's prognostic value for physical performance deterioration in community‐dwelling older adults, compare it with conventional measures (grip strength and MQI), determine whether MSS‐defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examine associations between MSS and key cardiometabolic and inflammatory biomarkers.

Source: Introduction Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

2.1

Participants and Study Design

The I‐Lan Longitudinal Aging Study (ILAS), initiated in 2011, is a prospective cohort study examining sarcopenia, frailty and cognitive function across ageing in community‐dwelling middle‐aged and older adults. Comprehensive descriptions of the study design and participant recruitment methods have been published previously [10, 11, 12]. Briefly, ILAS enrolled individuals aged 50 years or older who reside in Yuanshan Township, Yilan, Taiwan. ILAS recruited community residents aged 50 or older, excluding those unable to cooperate or communicate with researchers, unwilling to provide informed consent, institutionalized, functionally dependent or expected to live less than 6 months.

For the current study, data from the third and fourth waves of ILAS were retrieved for analysis. Of the original 2020 community‐dwelling older adults who underwent face‐to‐face interviews in 2020, 173 were excluded due to incomplete Bioelectrical Impedance Analysis (BIA) data in Wave 3. Besides, 19 participants were lost to follow‐up due to death, 22 due to incomplete data and 197 reluctant to participate. A total of 1609 participants were included in the final analysis (Figure 1).

FIGURE 1

Participant recruitment flowchart.

Figure image at the original source: open the original paper. This file is not included in this text import.

The institutional review board of Taipei Veterans General Hospital (2018‐05‐003B) approved the study protocol, and written informed consent was obtained from each individual before inclusion. This study was designed and conducted in accordance with the principles of the 1964 Declaration of Helsinki and later amendments. Reporting of this study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [13].

2.2

Muscle Mass Measurement

Body composition was assessed using multifrequency BIA (Inbody S10, Seoul, South Korea), measuring lean body mass, estimated appendicular muscle mass and lean muscle mass of the dominant hand. Appendicular skeletal muscle mass (ASM) was derived by summing lean tissue mass from all four limbs, and skeletal muscle index was calculated as ASM divided by height squared (kg/m2). Low muscle mass was defined as a height‐adjusted skeletal muscle index below 7 kg/m2 for men and below 5.7 kg/m2 for women aged 65 years or older and below the lowest quintile thresholds (7.8 kg/m2 for men and 5.7 kg/m2 for women) for those younger than 65 years [5].

2.3

Definition of Grip Strength, Muscle‐Specific Strength, Muscle Quality Index and Sarcopenia

Hand grip strength (HGS) of the dominant hand was measured using a digital dynamometer (Smedley's Dynamo Meter; TTM, Tokyo, Japan), and the highest value among three trials was used for statistical analysis. MSS was calculated by dividing HGS by the lean muscle mass of the dominant hand. The MQI was defined as HGS divided by ASM.

Low MSS and low MQI were defined as values within the lowest quintile, stratified by sex and age group (< 65 years and ≥ 65 years). Low MSS was defined as < 11.9 kg/kg for males and < 10.9 kg/kg for females aged < 65 years and < 11.0 kg/kg for males and < 10.6 kg/kg for females aged ≥ 65 years. Low MQI was defined as < 1.45 kg/kg for males and < 1.39 kg/kg for females aged < 65 years and < 1.38 kg/kg for both sexes aged ≥ 65 years.

Low HGS was defined as < 28 kg for men and < 18 kg for women aged 65 years or older and below the lowest quintile thresholds (< 33.8 kg for men and < 21.4 kg for women) for those younger than 65 years [5].

Sarcopenia was defined as the coexistence of low muscle strength and low muscle mass. Based on the specific definitions of muscle strength, we further categorized sarcopenia into three subtypes: (1) HGS‐sarcopenia, defined as low HGS plus low muscle mass; (2) MSS‐sarcopenia, defined as low MSS plus low muscle mass; and (3) MQI‐sarcopenia, defined as low MQI plus low muscle mass.

2.4

Outcome Measurement

GLIS suggests that physical performance should be considered an optimal health outcome rather than a diagnostic component of sarcopenia, given its susceptibility to influence by neuronal and other nonmuscular factors [14]. Therefore, we selected physical performance as the primary outcome in this study. Impaired physical performance was defined as taking 12 s or more to complete five chair stand repetitions, in accordance with the criteria from AWGS 2019 and GLIS [5, 6].

2.5

Functional Assessment

Research nurses collected demographic data, anthropometric measurements and functional assessments through face‐to‐face interviews. The collected information included age, sex, educational level, smoking and drinking habits. Standardized assessments were also conducted, including the Mini‐Nutritional Assessment (MNA) to evaluate nutritional status [15], the Center for Epidemiological Studies Depression Scale (CES‐D) to assess depressive symptoms [16] and the Mini‐Mental State Examination (MMSE) to evaluate cognitive function [17]. In addition, the Functional Autonomy Measurement System (SMAF) was used to assess activities of daily living (ADL) and instrumental activities of daily living (IADL) [18], and the Charlson Comorbidity Index (CCI) was applied to quantify disease burden [19].

2.6

Laboratory Data

Peripheral venous blood samples were collected after a 10‐h overnight fast. A broad range of biomarkers was analysed to assess cardiometabolic health, hormonal profiles and inflammatory status. These biomarkers included fasting glucose, glycated haemoglobin, total cholesterol, triglycerides, low‐density lipoprotein (LDL), insulin resistance estimated by the homeostasis model assessment (HOMA‐IR) and insulin secretory capacity assessed by the homeostatic model assessment of β‐cell function HOMA‐β [20]. Inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio, homocysteine and high‐sensitivity C‐reactive protein (hsCRP) were also measured.

Levels of age‐related hormones, including insulin‐like growth factor 1 (IGF‐1), and micronutrients such as vitamin D (25‐hydroxyvitamin D) were assessed. Technical specifications, including assay equipment and intraassay and interassay coefficients of variation, are detailed in Table S1.

2.7

Statistical Analysis

In this study, continuous variables were presented as means with standard deviations, and categorical variables were summarized as counts and percentages. Descriptive statistics were compared using Student's t test for continuous variables and chi‐square or Fisher's exact test for categorical variables, as appropriate.

MSS, HGS, MQI and sarcopenia defined by low strength, low MSS or low MQI were treated as categorical variables to assess their associations with impaired physical performance through logistic regression analysis. Multinomial logistic regression was employed to examine associations between MSS and baseline biomarker tertiles. Inverse probability weighting was applied as a sensitivity analysis to handle missing data. Subgroup analyses were conducted based on age (< 65 vs. ≥ 65 years), sex (male vs. female), diabetes mellitus (yes vs. no) and hypertension (yes vs. no).

We conducted additional analyses to account for adiposity by incorporating models of sarcopenic obesity and MSS‐defined sarcopenic obesity. Sarcopenic obesity was defined as the coexistence of low muscle mass and excessive adiposity, based on criteria from previous studies [12]. We also performed multivariable logistic regression including MSS and body fat percentage simultaneously to evaluate their independent associations with impaired physical performance. For all tests, statistical significance was defined as a two‐sided p value < 0.05 and a 95% confidence interval that did not include the null value.

All statistical analyses were performed using SAS software, Version 9.4 (SAS Institute Inc., Cary, NC, United States).

Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods

Baseline Characteristics of Study Participants

Results: Baseline Characteristics of Study Participants

A total of 1609 participants were included, with 320 (19.9%) classified as having low MSS (Table 1). During the follow‐up period, 731 participants (45.4%) experienced physical performance decline. Participants with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 kg/m2 vs. 7.1 ± 1.2 kg/m2, p < 0.001, and dominant hand muscle mass, 2.7 ± 0.8 kg vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 kg vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size.

Individuals in the low MSS group exhibited poorer cognitive function (MMSE, 26.9 ± 3.8 vs. 27.9 ± 2.5, p < 0.001), higher body mass index and higher percentages of hypertension (41.9% vs. 29.3%, p < 0.001) and diabetes (20.9% vs. 12.8%, p < 0.001). No significant differences were observed in age, nutritional status, depressive symptoms, functional activities, comorbidity burden or other chronic conditions (Table 1).

TABLE 1

Baseline characteristics of participants stratified by muscle strength.

Characteristics: Data show mean ± standard deviation or number (%)Muscle specific strength (MSS)Hand grip strength (HGS)
Low MSS (n = 320)Normal MSS (n = 1289) p valueLow HGS (n = 267)Normal HGS (n = 1342) p value
Demographic and lifestyle factors
Age (years)65.4 ± 7.864.5 ± 6.70.05565.1 ± 7.864.6 ± 0.20.266
Male162 (50.6)650 (50.5)1133 (49.8)680 (50.7)0.841
Education level< 0.0010.784
Below elementary school107 (33.4)288 (22.3)70 (26.2)325 (24.2)
Junior high school50 (15.6)205 (15.9)41 (15.4)214 (16.0)
Above high school163 (50.9)796 (61.8)156 (58.4)803 (59.8)
Current alcohol76 (23.8)311 (24.1)0.94255 (20.6)332 (24.7)0.159
Current tobacco smoker35 (10.9)107 (8.3)0.15229 (10.6)113 (8.4)0.195
Body mass index (kg/m2)26.4 ± 3.723.9 ± 3.0< 0.00123.8 ± 3.224.5 ± 3.30.003
Medical history
Hypertension134 (41.9)377 (29.3)< 0.00185 (31.8)426 (31.7)1
Diabetes67 (20.9)165 (12.8)< 0.00137 (22.8)90 (13.8)0.007
Coronary artery disease12 (3.8)59 (4.6)0.6489 (3.4)62 (4.6)0.418
Stroke1 (0.3)15 (1.2)0.2212 (0.8)14 (1.0)1
COPD3 (0.9)4 (0.3)0.14607 (0.5)0.608
Chronic kidney disease3 (0.9)6 (0.5)0.39409 (0.7)0.371
Charlson comorbidity index0.3 ± 0.50.2 ± 0.50.1230.2 ± 0.50.2 ± 0.50.683
Functional assessments
Mini‐Mental State Examination26.9 ± 3.827.9 ± 2.5< 0.00127.1 ± 3.527.8 ± 2.70.001
Mini‐Nutrition Assessment27.3 ± 1.827.3 ± 1.70.46826.7 ± 2.027.4 ± 1.6< 0.001
Center for Epidemiological Studies Depression Scale1.1 ± 2.51.4 ± 3.80.0761.6 ± 3.71.2 ± 3.50.108
SMAF‐ADL−0.02 ± 0.28−0.01 ± 0.230.680−0.02 ± 0.31−0.01 ± 0.230.574
SMAF‐IADL−0.09 ± 0.77−0.05 ± 0.680.419−0.13 ± 0.93−0.04 ± 0.640.138
Muscle health parameters
Muscle‐specific strength9.7 ± 1.314.3 ± 2.3< 0.00111.0 ± 2.313.9 ± 2.6< 0.001
Grip strength (kg)26.1 ± 8.132.0 ± 8.8< 0.00123.0 ± 6.232.4 ± 8.6< 0.001
Skeletal muscle index (kg/m2)7.7 ± 1.27.1 ± 1.2< 0.0017.1 ± 1.17.3 ± 1.20.006
Dominant hand muscle mass (kg)2.7 ± 0.82.3 ± 0.6< 0.0012.1 ± 0.52.4 ± 0.7< 0.001
Impaired physical performance153 (47.8)374 (29.0)< 0.001111 (41.6)416 (31.0)0.001

Abbreviations: ADL, activities of daily living; HGS, hand grip strength; IADL, instrumental activities of daily living; MSS, muscle‐specific strength; SMAF, functional autonomy measurement system.

Table S2 compares baseline characteristics across participants classified using three sarcopenia definitions: MSS‐sarcopenia, HGS‐based sarcopenia and MQI‐sarcopenia. Participants with MSS‐sarcopenia had significantly lower BMI, poorer nutritional status (MNA score) and reduced muscle mass and strength compared to those without MSS‐sarcopenia. MQI‐sarcopenia and HGS‐based sarcopenia shared similar trends to MSS‐sarcopenia but identified fewer individuals.

Source: Baseline Characteristics of Study Participants Source: Baseline Characteristics of Study Participants Source: Baseline Characteristics of Study Participants

Association of MSS and Sarcopenia With Adverse Outcomes

Results: Association of MSS and Sarcopenia With Adverse Outcomes

Full adjusted multiple logistic regression analyses explored the relationship between MSS and impaired physical performance (Figure 2). The findings indicate that low MSS is associated with a 49% increased risk of impaired physical performance (p = 0.008), whereas low HGS and low MQI were not significantly associated. MSS‐sarcopenia was significantly associated with impaired physical performance (OR 3.31, 95% CI: 1.26 to 8.74, p = 0.015), whereas MQI‐sarcopenia and HGS‐sarcopenia were not statistically significant (Figure 2 and Table S3). Results from the sensitivity analysis using inverse probability weighting to account for missing follow‐up data were consistent with the primary findings (Figure S1).

FIGURE 2

Impact of different strengths and different types of sarcopenia on physical functional impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Association of MSS and Sarcopenia With Adverse Outcomes Source: Association of MSS and Sarcopenia With Adverse Outcomes

Subgroup Analysis of MSS and Impaired Physical Performance

Results: Subgroup Analysis of MSS and Impaired Physical Performance

In the subgroup analysis, low MSS was significantly associated with impaired physical performance in men (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018), adults aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and individuals without diabetes (OR = 1.52, 95% CI: 1.10 to 2.11, p = 0.011). However, no significant associations were found among women, participants under 65 years of age or individuals with or without hypertension and with diabetes (Figure 3 and Table S4).

FIGURE 3

Impact of muscle‐specific strength subgroup on physical performance impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.

Both sarcopenic obesity and MSS‐defined sarcopenic obesity were significantly associated with higher odds of impaired physical performance (Figure S2). In models simultaneously adjusting for MSS and body fat percentage, MSS remained independently associated with impaired physical performance (adjusted OR = 1.36, 95% CI: 1.01 to 1.83, p = 0.041), indicating its predictive value beyond adiposity.

Source: Subgroup Analysis of MSS and Impaired Physical Performance Source: Subgroup Analysis of MSS and Impaired Physical Performance Source: Subgroup Analysis of MSS and Impaired Physical Performance

Association of Muscle‐Specific Strength With Biomarkers

Results: Association of Muscle‐Specific Strength With Biomarkers

Participants with low MSS had significantly higher levels of fasting glucose, HbA1c, HOMA‐IR, triglycerides and LDL‐C, alongside lower levels of HDL‐C and total cholesterol (TC), indicating a more adverse cardiometabolic profile. No significant differences were observed in ageing‐related biomarkers (IGF‐1, vitamin D) or most inflammatory markers, except for a trend towards higher hsCRP levels (Table S5). Cardiometabolic risk factors and chronic inflammatory biomarkers were dichotomized into tertiles to examine the associations between baseline biomarker levels and low MSS. Full adjusted multinomial logistic regression showed that higher fasting glucose was significantly associated with low MSS (OR = 1.55, 95% CI: 1.11 to 2.16, p = 0.011).

Similarly, elevated HbA1c (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.003) and increased insulin resistance, as measured by HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001), were also significantly associated with low MSS. HOMA‐β showed a negative association with MSS, with lower insulin secretory capacity linked to higher odds of low MSS (OR = 1.94, 95% CI: 1.41 to 2.67, p < 0.001). Additionally, higher TC (OR = 0.70, 95% CI: 0.49 to 0.98, p = 0.040) and elevated HDL (OR = 0.65, 95% CI: 0.46 to 0.91, p = 0.012) were also linked to low MSS.

Among chronic inflammatory biomarkers, hsCRP showed a positive association with low MSS (OR = 1.75, 95% CI: 1.28 to 2.39, p = 0.001) (Figure 4 and Table S5).

FIGURE 4

Multinomial logistic regressions explore associations between muscle‐specific strength and biomarkers.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Association of Muscle‐Specific Strength With Biomarkers Source: Association of Muscle‐Specific Strength With Biomarkers

Discussion

This study demonstrates that MSS, calculated as grip strength adjusted by the lean muscle mass of the dominant hand, predicts impaired physical performance over a 3‐year follow‐up more effectively than HGS or MQI. When combined with low muscle mass, MSS‐defined sarcopenia showed a stronger predictive value than traditional definitions of sarcopenia. This highlights the potential of MSS as an early clinical marker of muscle function, in line with the recommendations of the GLIS. Subgroup analyses revealed a higher risk among older adults and males, likely reflecting sex‐specific physiological differences and age‐related disparities in the rate of muscle decline.

Furthermore, significant associations between MSS and cardiometabolic and inflammatory markers: such as fasting glucose, HOMA‐IR and hsCRP: support metabolic dysregulation and chronic inflammation as underlying pathophysiological mechanisms affecting muscle health [21].

The recent Delphi consensus from the GLIS has recognized MSS: defined as strength normalized to muscle size: as a diagnostic component of sarcopenia, alongside muscle mass and strength [6]. This landmark consensus reflects growing recognition that sarcopenia is not solely a disorder of reduced muscle quantity but also of diminished functional capacity relative to muscle size. Our study provides timely and robust empirical support for prioritizing MSS in the sarcopenia diagnosis and extends its clinical relevance by demonstrating MSS as a practical, performance‐linked and biologically meaningful metric.

MSS integrates both functional and structural dimensions of skeletal muscle by normalizing strength measurements to muscle mass, thereby quantifying contractile efficiency and facilitating identification of individuals with preserved muscle mass but diminished functional capacity. Furthermore, MSS‐based sarcopenia was more predictive of functional impairment than conventional sarcopenia definitions or MQI‐sarcopenia. These findings underscore the potential of MSS to serve as a more sensitive and specific indicator for sarcopenia diagnosis.

Muscle strength declines much earlier than muscle mass with age, leading to a mismatch that becomes more pronounced over time [22, 23]. This discrepancy underscores the clinical relevance of MSS, a metric that reflects the efficiency of force generation relative to muscle size. Our study found that low MSS was significantly associated with impaired physical performance in older adults but not in middle‐aged individuals. This age‐specific pattern suggests that MSS better captures ageing‐related neuromuscular deterioration that is not yet apparent in midlife.

The stronger association between MSS and poor physical function in older adults may reflect physiological changes such as reduced motor unit recruitment, loss of maximal oxygen consumption and shifts in muscle composition [24]. These changes likely diminish the ability of older adults to compensate for declining muscle composition, making MSS a more sensitive indicator of early vulnerability. In contrast, middle‐aged individuals may still possess sufficient muscle reserve and functional adaptability to mask subtle declines in muscle quality. Our findings support that MSS may serve as an early marker of functional impairment risk, identifying older adults with hidden muscle inefficiency despite normal mass or strength.

Sex‐specific differences in muscle biology and body composition necessitate separate analyses in sarcopenia research to improve understanding and intervention strategies. Haizlip et al. [25] described intrinsic sex differences in muscle fibre composition and contractility, which may partly explain divergent patterns in muscle ageing. This distinction is particularly important in Asian populations, where women tend to present higher adiposity and smaller body sizes than men [23], making them susceptible to sarcopenia via different mechanisms. Biomarker evidence further supports sex‐dependent mechanisms.

Myostatin, a negative regulator of muscle growth, has been associated with low skeletal muscle mass exclusively in men [26]. A recent review demonstrated that exercise‐induced activation of muscle stem cells occurs more prominently in men than in women [27]. Results of our study show that low MSS is associated with impaired physical performance in both sexes, with stronger effects in men. These observations underline the importance of considering sex‐specific biological and environmental factors in both research and clinical management of sarcopenia.

Moreover, several cardiometabolic and inflammatory biomarkers have been found to be significantly associated with MSS. Elevated markers of glucose metabolism (fasting glucose, HbA1c and HOMA‐IR) and lipid profile as increased TC and reduced HDL‐C were consistently observed among individuals with lower MSS. This finding was similar to the previous study, which reported a strong link between relative muscle strength and cardiometabolic profiles [28]. Furthermore, a recent omics‐based analysis reinforces the critical role of glucose dysregulation in mobility impairment, implicating metabolic shifts as potential drivers of muscle decline [29].

HOMA‐β was negatively associated with MSS. This relationship may be partly mediated by the inverse association between HOMA‐β and BMI, as individuals in the low MSS group exhibited significantly higher BMI [30]. Systemic low‐grade inflammation also emerged as a relevant factor. Higher levels of hsCRP were significantly linked with low MSS, supporting the concept of ‘inflammaging’: the chronic, smouldering inflammation that contributes to age‐related functional decline [31]. Even in a relatively healthy older population, elevated hsCRP may signal early inflammatory processes detrimental to muscle function.

Taken together, these biomarker profiles reflect interconnected physiological disturbances: metabolic and inflammatory: that may contribute to the pathogenesis of muscle weakness.

Despite all the efforts carried out in the study, several limitations should be acknowledged. First, the study participants were relatively healthy community‐dwelling adults, which may have led to higher baseline physical performance and underestimated the predictive value of MSS. Second, the follow‐up duration of approximately 3 years may not have been sufficient to detect longer‐term declines in physical function. Future studies with extended follow‐up are warranted to validate our findings. Third, although BIA is less accurate than gold‐standard imaging modalities such as CT or MRI, it remains a practical method for community‐based research due to its portability, low cost and ease of use [32].

Previous studies have demonstrated its reasonable validity when compared to dual‐energy X‐ray absorptiometry (DXA) [33]. In particular, DXA exhibits limited capacity to distinguish intramuscular adipose tissue from lean mass, potentially resulting in muscle mass overestimation, especially among Asian female populations who demonstrate higher adiposity profiles. Despite the aforementioned limitations, this study demonstrates significant merit as the first prospective cohort study in Asia to compare different standardization approaches for HGS in predicting subsequent functional decline, providing critical insights for sarcopenia diagnosis, suggesting that MSS may warrant prioritization over absolute strength measurements.

In conclusion, this study highlights MSS: grip strength normalized to dominant hand muscle mass: as a sensitive and effective marker of impaired physical performance. MSS outperformed conventional measures and showed a stronger link to impaired function than HGS‐ and MQI‐defined sarcopenia. Its association with unfavourable cardiometabolic and inflammatory profiles supports MSS as a biologically plausible indicator of muscle health. Given its simplicity and predictive value, MSS may be a useful tool for early detection and monitoring of muscle health in ageing.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

3.1

Baseline Characteristics of Study Participants

A total of 1609 participants were included, with 320 (19.9%) classified as having low MSS (Table 1). During the follow‐up period, 731 participants (45.4%) experienced physical performance decline. Participants with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 kg/m2 vs. 7.1 ± 1.2 kg/m2, p < 0.001, and dominant hand muscle mass, 2.7 ± 0.8 kg vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 kg vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size.

Individuals in the low MSS group exhibited poorer cognitive function (MMSE, 26.9 ± 3.8 vs. 27.9 ± 2.5, p < 0.001), higher body mass index and higher percentages of hypertension (41.9% vs. 29.3%, p < 0.001) and diabetes (20.9% vs. 12.8%, p < 0.001). No significant differences were observed in age, nutritional status, depressive symptoms, functional activities, comorbidity burden or other chronic conditions (Table 1).

TABLE 1

Baseline characteristics of participants stratified by muscle strength.

Characteristics: Data show mean ± standard deviation or number (%)Muscle specific strength (MSS)Hand grip strength (HGS)
Low MSS (n = 320)Normal MSS (n = 1289) p valueLow HGS (n = 267)Normal HGS (n = 1342) p value
Demographic and lifestyle factors
Age (years)65.4 ± 7.864.5 ± 6.70.05565.1 ± 7.864.6 ± 0.20.266
Male162 (50.6)650 (50.5)1133 (49.8)680 (50.7)0.841
Education level< 0.0010.784
Below elementary school107 (33.4)288 (22.3)70 (26.2)325 (24.2)
Junior high school50 (15.6)205 (15.9)41 (15.4)214 (16.0)
Above high school163 (50.9)796 (61.8)156 (58.4)803 (59.8)
Current alcohol76 (23.8)311 (24.1)0.94255 (20.6)332 (24.7)0.159
Current tobacco smoker35 (10.9)107 (8.3)0.15229 (10.6)113 (8.4)0.195
Body mass index (kg/m2)26.4 ± 3.723.9 ± 3.0< 0.00123.8 ± 3.224.5 ± 3.30.003
Medical history
Hypertension134 (41.9)377 (29.3)< 0.00185 (31.8)426 (31.7)1
Diabetes67 (20.9)165 (12.8)< 0.00137 (22.8)90 (13.8)0.007
Coronary artery disease12 (3.8)59 (4.6)0.6489 (3.4)62 (4.6)0.418
Stroke1 (0.3)15 (1.2)0.2212 (0.8)14 (1.0)1
COPD3 (0.9)4 (0.3)0.14607 (0.5)0.608
Chronic kidney disease3 (0.9)6 (0.5)0.39409 (0.7)0.371
Charlson comorbidity index0.3 ± 0.50.2 ± 0.50.1230.2 ± 0.50.2 ± 0.50.683
Functional assessments
Mini‐Mental State Examination26.9 ± 3.827.9 ± 2.5< 0.00127.1 ± 3.527.8 ± 2.70.001
Mini‐Nutrition Assessment27.3 ± 1.827.3 ± 1.70.46826.7 ± 2.027.4 ± 1.6< 0.001
Center for Epidemiological Studies Depression Scale1.1 ± 2.51.4 ± 3.80.0761.6 ± 3.71.2 ± 3.50.108
SMAF‐ADL−0.02 ± 0.28−0.01 ± 0.230.680−0.02 ± 0.31−0.01 ± 0.230.574
SMAF‐IADL−0.09 ± 0.77−0.05 ± 0.680.419−0.13 ± 0.93−0.04 ± 0.640.138
Muscle health parameters
Muscle‐specific strength9.7 ± 1.314.3 ± 2.3< 0.00111.0 ± 2.313.9 ± 2.6< 0.001
Grip strength (kg)26.1 ± 8.132.0 ± 8.8< 0.00123.0 ± 6.232.4 ± 8.6< 0.001
Skeletal muscle index (kg/m2)7.7 ± 1.27.1 ± 1.2< 0.0017.1 ± 1.17.3 ± 1.20.006
Dominant hand muscle mass (kg)2.7 ± 0.82.3 ± 0.6< 0.0012.1 ± 0.52.4 ± 0.7< 0.001
Impaired physical performance153 (47.8)374 (29.0)< 0.001111 (41.6)416 (31.0)0.001

Abbreviations: ADL, activities of daily living; HGS, hand grip strength; IADL, instrumental activities of daily living; MSS, muscle‐specific strength; SMAF, functional autonomy measurement system.

Table S2 compares baseline characteristics across participants classified using three sarcopenia definitions: MSS‐sarcopenia, HGS‐based sarcopenia and MQI‐sarcopenia. Participants with MSS‐sarcopenia had significantly lower BMI, poorer nutritional status (MNA score) and reduced muscle mass and strength compared to those without MSS‐sarcopenia. MQI‐sarcopenia and HGS‐based sarcopenia shared similar trends to MSS‐sarcopenia but identified fewer individuals.

3.2

Association of MSS and Sarcopenia With Adverse Outcomes

Full adjusted multiple logistic regression analyses explored the relationship between MSS and impaired physical performance (Figure 2). The findings indicate that low MSS is associated with a 49% increased risk of impaired physical performance (p = 0.008), whereas low HGS and low MQI were not significantly associated. MSS‐sarcopenia was significantly associated with impaired physical performance (OR 3.31, 95% CI: 1.26 to 8.74, p = 0.015), whereas MQI‐sarcopenia and HGS‐sarcopenia were not statistically significant (Figure 2 and Table S3). Results from the sensitivity analysis using inverse probability weighting to account for missing follow‐up data were consistent with the primary findings (Figure S1).

FIGURE 2

Impact of different strengths and different types of sarcopenia on physical functional impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3

Subgroup Analysis of MSS and Impaired Physical Performance

In the subgroup analysis, low MSS was significantly associated with impaired physical performance in men (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018), adults aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and individuals without diabetes (OR = 1.52, 95% CI: 1.10 to 2.11, p = 0.011). However, no significant associations were found among women, participants under 65 years of age or individuals with or without hypertension and with diabetes (Figure 3 and Table S4).

FIGURE 3

Impact of muscle‐specific strength subgroup on physical performance impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.

Both sarcopenic obesity and MSS‐defined sarcopenic obesity were significantly associated with higher odds of impaired physical performance (Figure S2). In models simultaneously adjusting for MSS and body fat percentage, MSS remained independently associated with impaired physical performance (adjusted OR = 1.36, 95% CI: 1.01 to 1.83, p = 0.041), indicating its predictive value beyond adiposity.

3.4

Association of Muscle‐Specific Strength With Biomarkers

Participants with low MSS had significantly higher levels of fasting glucose, HbA1c, HOMA‐IR, triglycerides and LDL‐C, alongside lower levels of HDL‐C and total cholesterol (TC), indicating a more adverse cardiometabolic profile. No significant differences were observed in ageing‐related biomarkers (IGF‐1, vitamin D) or most inflammatory markers, except for a trend towards higher hsCRP levels (Table S5). Cardiometabolic risk factors and chronic inflammatory biomarkers were dichotomized into tertiles to examine the associations between baseline biomarker levels and low MSS. Full adjusted multinomial logistic regression showed that higher fasting glucose was significantly associated with low MSS (OR = 1.55, 95% CI: 1.11 to 2.16, p = 0.011).

Similarly, elevated HbA1c (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.003) and increased insulin resistance, as measured by HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001), were also significantly associated with low MSS. HOMA‐β showed a negative association with MSS, with lower insulin secretory capacity linked to higher odds of low MSS (OR = 1.94, 95% CI: 1.41 to 2.67, p < 0.001). Additionally, higher TC (OR = 0.70, 95% CI: 0.49 to 0.98, p = 0.040) and elevated HDL (OR = 0.65, 95% CI: 0.46 to 0.91, p = 0.012) were also linked to low MSS.

Among chronic inflammatory biomarkers, hsCRP showed a positive association with low MSS (OR = 1.75, 95% CI: 1.28 to 2.39, p = 0.001) (Figure 4 and Table S5).

FIGURE 4

Multinomial logistic regressions explore associations between muscle‐specific strength and biomarkers.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusions

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

Source: Conclusions
Authors’ abstract

ABSTRACT

Background

Muscle‐specific strength (MSS), defined as grip strength normalized to arm muscle mass, may better reflect muscle efficiency than grip strength. Despite its potential utility in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia‐related outcomes remain limited. This study investigated the associations of MSS with physical performance deterioration and biomarker profiles in community‐dwelling older adults, compared it with conventional measures, determined whether MSS‐defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examined associations with key cardiometabolic and inflammatory biomarkers.

Methods

This prospective cohort study included 1609 participants (mean age 64.5 ± 6.7 years; 50.5% male) from the I‐Lan Longitudinal Aging Study. MSS was calculated by dividing handgrip strength by dominant arm muscle mass. Participants were categorized into low and normal MSS groups using age‐sex‐specific cutoffs based on quintiles. Physical function was assessed using the five‐time chair stand test, with impaired physical performance (PPI) defined as taking ≥ 12 s. Logistic regression models examined the associations between MSS and PPI, adjusted for demographics, comorbidities, cognitive function and skeletal muscle index.

Biomarker profiles, including metabolic, inflammatory and hormonal parameters, were compared across MSS groups.

Results

Low MSS was found in 19.9% of participants. Those with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 vs. 7.1 ± 1.2 kg/m2, p < 0.001; dominant hand muscle mass, 2.7 ± 0.8 vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size. PPI was more common in the low MSS group (47.8% vs. 29.0%, p < 0.001).

Low MSS was significantly associated with higher odds of PPI (adjusted OR = 1.49, 95% CI: 1.11 to 1.99, p = 0.008), particularly among participants aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and males (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018). MSS‐defined sarcopenia showed a stronger association with PPI (OR = 3.31, 95% CI: 1.26 to 8.74, p = 0.015) than conventional sarcopenia definitions. Individuals with low MSS demonstrated adverse metabolic profiles, including higher fasting glucose (101.0 ± 27.3 vs. 95.0 ± 18.7 mg/dL, p < 0.001), HbA1c (6.0% ± 0.9% vs. 5.8% ± 0.7%, p < 0.001) and HOMA‐IR (2.6 ± 2.2 vs. 1.8 ± 1.4, p < 0.001).

In adjusted models, high HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001) and elevated hsCRP (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.001) were strongly associated with low MSS.

Conclusions

Low MSS independently predicts physical performance deterioration and associates with adverse metabolic and inflammatory biomarker profiles in older adults. MSS may better indicate muscle health than traditional metrics, supporting its inclusion in sarcopenia assessment frameworks as recommended by recent consensus guidelines.

Read the full paper
1

Introduction

Sarcopenia, characterized by the age‐related progressive loss of muscle mass and function, significantly increases the risk of impaired physical performance, disability, reduced quality of life and mortality among older adults [1, 2]. Previously, sarcopenia assessment has relied on separate measurements of muscle mass or function [3]. Yet, taken alone, these indicators often fall short in capturing overall muscle function. Therefore, current consensus definitions of sarcopenia, including those from the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS 2019), emphasize combined muscle mass, muscle strength and physical performance as the diagnostic components [4, 5].

Recently, the Global Leadership Initiative on Sarcopenia (GLIS) has proposed a new diagnostic algorithm for sarcopenia that designates muscle strength or muscle‐specific strength (MSS) as the primary metric for assessing muscle function, while reclassifying physical performance parameters as outcome indicators of sarcopenic progression [6].

In addition to muscle strength, some researchers use the Muscle Quality Index (MQI): grip strength divided by total appendicular lean mass: as a marker of muscle efficiency [7, 8]. However, MQI has inherent limitations related to sex‐specific differences in muscle distribution and potential misclassification due to differences in body composition. Men typically carry relatively more muscle mass in the upper body, whereas women have a higher proportion of lean mass concentrated in the lower limbs [9]. Moreover, when grip strength is normalized to total lean mass, obese individuals may appear to have artificially low MQI values due to high leg mass inflating the denominator, despite having adequate upper limb strength.

MSS, defined as grip strength normalized specifically to upper limb lean mass, reduces the biases derived from MQI. Despite the potential utility of MSS in diagnosing sarcopenia, longitudinal studies evaluating MSS as a predictor of sarcopenia‐related outcomes remain scarce, particularly among Asian populations, thus limiting the clinical application of MSS as a diagnostic criterion for sarcopenia. This current study aimed to evaluate MSS's prognostic value for physical performance deterioration in community‐dwelling older adults, compare it with conventional measures (grip strength and MQI), determine whether MSS‐defined sarcopenia offers superior predictive utility versus traditional diagnostic criteria and examine associations between MSS and key cardiometabolic and inflammatory biomarkers.

2

Methods

2.1

Participants and Study Design

The I‐Lan Longitudinal Aging Study (ILAS), initiated in 2011, is a prospective cohort study examining sarcopenia, frailty and cognitive function across ageing in community‐dwelling middle‐aged and older adults. Comprehensive descriptions of the study design and participant recruitment methods have been published previously [10, 11, 12]. Briefly, ILAS enrolled individuals aged 50 years or older who reside in Yuanshan Township, Yilan, Taiwan. ILAS recruited community residents aged 50 or older, excluding those unable to cooperate or communicate with researchers, unwilling to provide informed consent, institutionalized, functionally dependent or expected to live less than 6 months.

For the current study, data from the third and fourth waves of ILAS were retrieved for analysis. Of the original 2020 community‐dwelling older adults who underwent face‐to‐face interviews in 2020, 173 were excluded due to incomplete Bioelectrical Impedance Analysis (BIA) data in Wave 3. Besides, 19 participants were lost to follow‐up due to death, 22 due to incomplete data and 197 reluctant to participate. A total of 1609 participants were included in the final analysis (Figure 1).

FIGURE 1

Participant recruitment flowchart.

Figure image at the original source: open the original paper. This file is not included in this text import.

The institutional review board of Taipei Veterans General Hospital (2018‐05‐003B) approved the study protocol, and written informed consent was obtained from each individual before inclusion. This study was designed and conducted in accordance with the principles of the 1964 Declaration of Helsinki and later amendments. Reporting of this study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [13].

2.2

Muscle Mass Measurement

Body composition was assessed using multifrequency BIA (Inbody S10, Seoul, South Korea), measuring lean body mass, estimated appendicular muscle mass and lean muscle mass of the dominant hand. Appendicular skeletal muscle mass (ASM) was derived by summing lean tissue mass from all four limbs, and skeletal muscle index was calculated as ASM divided by height squared (kg/m2). Low muscle mass was defined as a height‐adjusted skeletal muscle index below 7 kg/m2 for men and below 5.7 kg/m2 for women aged 65 years or older and below the lowest quintile thresholds (7.8 kg/m2 for men and 5.7 kg/m2 for women) for those younger than 65 years [5].

2.3

Definition of Grip Strength, Muscle‐Specific Strength, Muscle Quality Index and Sarcopenia

Hand grip strength (HGS) of the dominant hand was measured using a digital dynamometer (Smedley's Dynamo Meter; TTM, Tokyo, Japan), and the highest value among three trials was used for statistical analysis. MSS was calculated by dividing HGS by the lean muscle mass of the dominant hand. The MQI was defined as HGS divided by ASM.

Low MSS and low MQI were defined as values within the lowest quintile, stratified by sex and age group (< 65 years and ≥ 65 years). Low MSS was defined as < 11.9 kg/kg for males and < 10.9 kg/kg for females aged < 65 years and < 11.0 kg/kg for males and < 10.6 kg/kg for females aged ≥ 65 years. Low MQI was defined as < 1.45 kg/kg for males and < 1.39 kg/kg for females aged < 65 years and < 1.38 kg/kg for both sexes aged ≥ 65 years.

Low HGS was defined as < 28 kg for men and < 18 kg for women aged 65 years or older and below the lowest quintile thresholds (< 33.8 kg for men and < 21.4 kg for women) for those younger than 65 years [5].

Sarcopenia was defined as the coexistence of low muscle strength and low muscle mass. Based on the specific definitions of muscle strength, we further categorized sarcopenia into three subtypes: (1) HGS‐sarcopenia, defined as low HGS plus low muscle mass; (2) MSS‐sarcopenia, defined as low MSS plus low muscle mass; and (3) MQI‐sarcopenia, defined as low MQI plus low muscle mass.

2.4

Outcome Measurement

GLIS suggests that physical performance should be considered an optimal health outcome rather than a diagnostic component of sarcopenia, given its susceptibility to influence by neuronal and other nonmuscular factors [14]. Therefore, we selected physical performance as the primary outcome in this study. Impaired physical performance was defined as taking 12 s or more to complete five chair stand repetitions, in accordance with the criteria from AWGS 2019 and GLIS [5, 6].

2.5

Functional Assessment

Research nurses collected demographic data, anthropometric measurements and functional assessments through face‐to‐face interviews. The collected information included age, sex, educational level, smoking and drinking habits. Standardized assessments were also conducted, including the Mini‐Nutritional Assessment (MNA) to evaluate nutritional status [15], the Center for Epidemiological Studies Depression Scale (CES‐D) to assess depressive symptoms [16] and the Mini‐Mental State Examination (MMSE) to evaluate cognitive function [17]. In addition, the Functional Autonomy Measurement System (SMAF) was used to assess activities of daily living (ADL) and instrumental activities of daily living (IADL) [18], and the Charlson Comorbidity Index (CCI) was applied to quantify disease burden [19].

2.6

Laboratory Data

Peripheral venous blood samples were collected after a 10‐h overnight fast. A broad range of biomarkers was analysed to assess cardiometabolic health, hormonal profiles and inflammatory status. These biomarkers included fasting glucose, glycated haemoglobin, total cholesterol, triglycerides, low‐density lipoprotein (LDL), insulin resistance estimated by the homeostasis model assessment (HOMA‐IR) and insulin secretory capacity assessed by the homeostatic model assessment of β‐cell function HOMA‐β [20]. Inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio, homocysteine and high‐sensitivity C‐reactive protein (hsCRP) were also measured.

Levels of age‐related hormones, including insulin‐like growth factor 1 (IGF‐1), and micronutrients such as vitamin D (25‐hydroxyvitamin D) were assessed. Technical specifications, including assay equipment and intraassay and interassay coefficients of variation, are detailed in Table S1.

2.7

Statistical Analysis

In this study, continuous variables were presented as means with standard deviations, and categorical variables were summarized as counts and percentages. Descriptive statistics were compared using Student's t test for continuous variables and chi‐square or Fisher's exact test for categorical variables, as appropriate.

MSS, HGS, MQI and sarcopenia defined by low strength, low MSS or low MQI were treated as categorical variables to assess their associations with impaired physical performance through logistic regression analysis. Multinomial logistic regression was employed to examine associations between MSS and baseline biomarker tertiles. Inverse probability weighting was applied as a sensitivity analysis to handle missing data. Subgroup analyses were conducted based on age (< 65 vs. ≥ 65 years), sex (male vs. female), diabetes mellitus (yes vs. no) and hypertension (yes vs. no).

We conducted additional analyses to account for adiposity by incorporating models of sarcopenic obesity and MSS‐defined sarcopenic obesity. Sarcopenic obesity was defined as the coexistence of low muscle mass and excessive adiposity, based on criteria from previous studies [12]. We also performed multivariable logistic regression including MSS and body fat percentage simultaneously to evaluate their independent associations with impaired physical performance. For all tests, statistical significance was defined as a two‐sided p value < 0.05 and a 95% confidence interval that did not include the null value.

All statistical analyses were performed using SAS software, Version 9.4 (SAS Institute Inc., Cary, NC, United States).

3

Results

3.1

Baseline Characteristics of Study Participants

A total of 1609 participants were included, with 320 (19.9%) classified as having low MSS (Table 1). During the follow‐up period, 731 participants (45.4%) experienced physical performance decline. Participants with low MSS had significantly higher muscle mass (skeletal muscle index, 7.7 ± 1.2 kg/m2 vs. 7.1 ± 1.2 kg/m2, p < 0.001, and dominant hand muscle mass, 2.7 ± 0.8 kg vs. 2.3 ± 0.6 kg, p < 0.001) but weaker grip strength (26.1 ± 8.1 kg vs. 32.0 ± 8.8 kg, p < 0.001), indicating disproportionately low strength relative to muscle size.

Individuals in the low MSS group exhibited poorer cognitive function (MMSE, 26.9 ± 3.8 vs. 27.9 ± 2.5, p < 0.001), higher body mass index and higher percentages of hypertension (41.9% vs. 29.3%, p < 0.001) and diabetes (20.9% vs. 12.8%, p < 0.001). No significant differences were observed in age, nutritional status, depressive symptoms, functional activities, comorbidity burden or other chronic conditions (Table 1).

TABLE 1

Baseline characteristics of participants stratified by muscle strength.

Characteristics: Data show mean ± standard deviation or number (%)Muscle specific strength (MSS)Hand grip strength (HGS)
Low MSS (n = 320)Normal MSS (n = 1289) p valueLow HGS (n = 267)Normal HGS (n = 1342) p value
Demographic and lifestyle factors
Age (years)65.4 ± 7.864.5 ± 6.70.05565.1 ± 7.864.6 ± 0.20.266
Male162 (50.6)650 (50.5)1133 (49.8)680 (50.7)0.841
Education level< 0.0010.784
Below elementary school107 (33.4)288 (22.3)70 (26.2)325 (24.2)
Junior high school50 (15.6)205 (15.9)41 (15.4)214 (16.0)
Above high school163 (50.9)796 (61.8)156 (58.4)803 (59.8)
Current alcohol76 (23.8)311 (24.1)0.94255 (20.6)332 (24.7)0.159
Current tobacco smoker35 (10.9)107 (8.3)0.15229 (10.6)113 (8.4)0.195
Body mass index (kg/m2)26.4 ± 3.723.9 ± 3.0< 0.00123.8 ± 3.224.5 ± 3.30.003
Medical history
Hypertension134 (41.9)377 (29.3)< 0.00185 (31.8)426 (31.7)1
Diabetes67 (20.9)165 (12.8)< 0.00137 (22.8)90 (13.8)0.007
Coronary artery disease12 (3.8)59 (4.6)0.6489 (3.4)62 (4.6)0.418
Stroke1 (0.3)15 (1.2)0.2212 (0.8)14 (1.0)1
COPD3 (0.9)4 (0.3)0.14607 (0.5)0.608
Chronic kidney disease3 (0.9)6 (0.5)0.39409 (0.7)0.371
Charlson comorbidity index0.3 ± 0.50.2 ± 0.50.1230.2 ± 0.50.2 ± 0.50.683
Functional assessments
Mini‐Mental State Examination26.9 ± 3.827.9 ± 2.5< 0.00127.1 ± 3.527.8 ± 2.70.001
Mini‐Nutrition Assessment27.3 ± 1.827.3 ± 1.70.46826.7 ± 2.027.4 ± 1.6< 0.001
Center for Epidemiological Studies Depression Scale1.1 ± 2.51.4 ± 3.80.0761.6 ± 3.71.2 ± 3.50.108
SMAF‐ADL−0.02 ± 0.28−0.01 ± 0.230.680−0.02 ± 0.31−0.01 ± 0.230.574
SMAF‐IADL−0.09 ± 0.77−0.05 ± 0.680.419−0.13 ± 0.93−0.04 ± 0.640.138
Muscle health parameters
Muscle‐specific strength9.7 ± 1.314.3 ± 2.3< 0.00111.0 ± 2.313.9 ± 2.6< 0.001
Grip strength (kg)26.1 ± 8.132.0 ± 8.8< 0.00123.0 ± 6.232.4 ± 8.6< 0.001
Skeletal muscle index (kg/m2)7.7 ± 1.27.1 ± 1.2< 0.0017.1 ± 1.17.3 ± 1.20.006
Dominant hand muscle mass (kg)2.7 ± 0.82.3 ± 0.6< 0.0012.1 ± 0.52.4 ± 0.7< 0.001
Impaired physical performance153 (47.8)374 (29.0)< 0.001111 (41.6)416 (31.0)0.001

Abbreviations: ADL, activities of daily living; HGS, hand grip strength; IADL, instrumental activities of daily living; MSS, muscle‐specific strength; SMAF, functional autonomy measurement system.

Table S2 compares baseline characteristics across participants classified using three sarcopenia definitions: MSS‐sarcopenia, HGS‐based sarcopenia and MQI‐sarcopenia. Participants with MSS‐sarcopenia had significantly lower BMI, poorer nutritional status (MNA score) and reduced muscle mass and strength compared to those without MSS‐sarcopenia. MQI‐sarcopenia and HGS‐based sarcopenia shared similar trends to MSS‐sarcopenia but identified fewer individuals.

3.2

Association of MSS and Sarcopenia With Adverse Outcomes

Full adjusted multiple logistic regression analyses explored the relationship between MSS and impaired physical performance (Figure 2). The findings indicate that low MSS is associated with a 49% increased risk of impaired physical performance (p = 0.008), whereas low HGS and low MQI were not significantly associated. MSS‐sarcopenia was significantly associated with impaired physical performance (OR 3.31, 95% CI: 1.26 to 8.74, p = 0.015), whereas MQI‐sarcopenia and HGS‐sarcopenia were not statistically significant (Figure 2 and Table S3). Results from the sensitivity analysis using inverse probability weighting to account for missing follow‐up data were consistent with the primary findings (Figure S1).

FIGURE 2

Impact of different strengths and different types of sarcopenia on physical functional impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3

Subgroup Analysis of MSS and Impaired Physical Performance

In the subgroup analysis, low MSS was significantly associated with impaired physical performance in men (OR = 1.64, 95% CI: 1.09 to 2.47, p = 0.018), adults aged ≥ 65 years (OR = 1.80, 95% CI: 1.18 to 2.74, p = 0.006) and individuals without diabetes (OR = 1.52, 95% CI: 1.10 to 2.11, p = 0.011). However, no significant associations were found among women, participants under 65 years of age or individuals with or without hypertension and with diabetes (Figure 3 and Table S4).

FIGURE 3

Impact of muscle‐specific strength subgroup on physical performance impairment.

Figure image at the original source: open the original paper. This file is not included in this text import.

Both sarcopenic obesity and MSS‐defined sarcopenic obesity were significantly associated with higher odds of impaired physical performance (Figure S2). In models simultaneously adjusting for MSS and body fat percentage, MSS remained independently associated with impaired physical performance (adjusted OR = 1.36, 95% CI: 1.01 to 1.83, p = 0.041), indicating its predictive value beyond adiposity.

3.4

Association of Muscle‐Specific Strength With Biomarkers

Participants with low MSS had significantly higher levels of fasting glucose, HbA1c, HOMA‐IR, triglycerides and LDL‐C, alongside lower levels of HDL‐C and total cholesterol (TC), indicating a more adverse cardiometabolic profile. No significant differences were observed in ageing‐related biomarkers (IGF‐1, vitamin D) or most inflammatory markers, except for a trend towards higher hsCRP levels (Table S5). Cardiometabolic risk factors and chronic inflammatory biomarkers were dichotomized into tertiles to examine the associations between baseline biomarker levels and low MSS. Full adjusted multinomial logistic regression showed that higher fasting glucose was significantly associated with low MSS (OR = 1.55, 95% CI: 1.11 to 2.16, p = 0.011).

Similarly, elevated HbA1c (OR = 1.66, 95% CI: 1.18 to 2.33, p = 0.003) and increased insulin resistance, as measured by HOMA‐IR (OR = 2.71, 95% CI: 1.94 to 3.79, p < 0.001), were also significantly associated with low MSS. HOMA‐β showed a negative association with MSS, with lower insulin secretory capacity linked to higher odds of low MSS (OR = 1.94, 95% CI: 1.41 to 2.67, p < 0.001). Additionally, higher TC (OR = 0.70, 95% CI: 0.49 to 0.98, p = 0.040) and elevated HDL (OR = 0.65, 95% CI: 0.46 to 0.91, p = 0.012) were also linked to low MSS.

Among chronic inflammatory biomarkers, hsCRP showed a positive association with low MSS (OR = 1.75, 95% CI: 1.28 to 2.39, p = 0.001) (Figure 4 and Table S5).

FIGURE 4

Multinomial logistic regressions explore associations between muscle‐specific strength and biomarkers.

Figure image at the original source: open the original paper. This file is not included in this text import.
4

Discussion

This study demonstrates that MSS, calculated as grip strength adjusted by the lean muscle mass of the dominant hand, predicts impaired physical performance over a 3‐year follow‐up more effectively than HGS or MQI. When combined with low muscle mass, MSS‐defined sarcopenia showed a stronger predictive value than traditional definitions of sarcopenia. This highlights the potential of MSS as an early clinical marker of muscle function, in line with the recommendations of the GLIS. Subgroup analyses revealed a higher risk among older adults and males, likely reflecting sex‐specific physiological differences and age‐related disparities in the rate of muscle decline.

Furthermore, significant associations between MSS and cardiometabolic and inflammatory markers: such as fasting glucose, HOMA‐IR and hsCRP: support metabolic dysregulation and chronic inflammation as underlying pathophysiological mechanisms affecting muscle health [21].

The recent Delphi consensus from the GLIS has recognized MSS: defined as strength normalized to muscle size: as a diagnostic component of sarcopenia, alongside muscle mass and strength [6]. This landmark consensus reflects growing recognition that sarcopenia is not solely a disorder of reduced muscle quantity but also of diminished functional capacity relative to muscle size. Our study provides timely and robust empirical support for prioritizing MSS in the sarcopenia diagnosis and extends its clinical relevance by demonstrating MSS as a practical, performance‐linked and biologically meaningful metric.

MSS integrates both functional and structural dimensions of skeletal muscle by normalizing strength measurements to muscle mass, thereby quantifying contractile efficiency and facilitating identification of individuals with preserved muscle mass but diminished functional capacity. Furthermore, MSS‐based sarcopenia was more predictive of functional impairment than conventional sarcopenia definitions or MQI‐sarcopenia. These findings underscore the potential of MSS to serve as a more sensitive and specific indicator for sarcopenia diagnosis.

Muscle strength declines much earlier than muscle mass with age, leading to a mismatch that becomes more pronounced over time [22, 23]. This discrepancy underscores the clinical relevance of MSS, a metric that reflects the efficiency of force generation relative to muscle size. Our study found that low MSS was significantly associated with impaired physical performance in older adults but not in middle‐aged individuals. This age‐specific pattern suggests that MSS better captures ageing‐related neuromuscular deterioration that is not yet apparent in midlife.

The stronger association between MSS and poor physical function in older adults may reflect physiological changes such as reduced motor unit recruitment, loss of maximal oxygen consumption and shifts in muscle composition [24]. These changes likely diminish the ability of older adults to compensate for declining muscle composition, making MSS a more sensitive indicator of early vulnerability. In contrast, middle‐aged individuals may still possess sufficient muscle reserve and functional adaptability to mask subtle declines in muscle quality. Our findings support that MSS may serve as an early marker of functional impairment risk, identifying older adults with hidden muscle inefficiency despite normal mass or strength.

Sex‐specific differences in muscle biology and body composition necessitate separate analyses in sarcopenia research to improve understanding and intervention strategies. Haizlip et al. [25] described intrinsic sex differences in muscle fibre composition and contractility, which may partly explain divergent patterns in muscle ageing. This distinction is particularly important in Asian populations, where women tend to present higher adiposity and smaller body sizes than men [23], making them susceptible to sarcopenia via different mechanisms. Biomarker evidence further supports sex‐dependent mechanisms.

Myostatin, a negative regulator of muscle growth, has been associated with low skeletal muscle mass exclusively in men [26]. A recent review demonstrated that exercise‐induced activation of muscle stem cells occurs more prominently in men than in women [27]. Results of our study show that low MSS is associated with impaired physical performance in both sexes, with stronger effects in men. These observations underline the importance of considering sex‐specific biological and environmental factors in both research and clinical management of sarcopenia.

Moreover, several cardiometabolic and inflammatory biomarkers have been found to be significantly associated with MSS. Elevated markers of glucose metabolism (fasting glucose, HbA1c and HOMA‐IR) and lipid profile as increased TC and reduced HDL‐C were consistently observed among individuals with lower MSS. This finding was similar to the previous study, which reported a strong link between relative muscle strength and cardiometabolic profiles [28]. Furthermore, a recent omics‐based analysis reinforces the critical role of glucose dysregulation in mobility impairment, implicating metabolic shifts as potential drivers of muscle decline [29].

HOMA‐β was negatively associated with MSS. This relationship may be partly mediated by the inverse association between HOMA‐β and BMI, as individuals in the low MSS group exhibited significantly higher BMI [30]. Systemic low‐grade inflammation also emerged as a relevant factor. Higher levels of hsCRP were significantly linked with low MSS, supporting the concept of ‘inflammaging’: the chronic, smouldering inflammation that contributes to age‐related functional decline [31]. Even in a relatively healthy older population, elevated hsCRP may signal early inflammatory processes detrimental to muscle function.

Taken together, these biomarker profiles reflect interconnected physiological disturbances: metabolic and inflammatory: that may contribute to the pathogenesis of muscle weakness.

Despite all the efforts carried out in the study, several limitations should be acknowledged. First, the study participants were relatively healthy community‐dwelling adults, which may have led to higher baseline physical performance and underestimated the predictive value of MSS. Second, the follow‐up duration of approximately 3 years may not have been sufficient to detect longer‐term declines in physical function. Future studies with extended follow‐up are warranted to validate our findings. Third, although BIA is less accurate than gold‐standard imaging modalities such as CT or MRI, it remains a practical method for community‐based research due to its portability, low cost and ease of use [32].

Previous studies have demonstrated its reasonable validity when compared to dual‐energy X‐ray absorptiometry (DXA) [33]. In particular, DXA exhibits limited capacity to distinguish intramuscular adipose tissue from lean mass, potentially resulting in muscle mass overestimation, especially among Asian female populations who demonstrate higher adiposity profiles. Despite the aforementioned limitations, this study demonstrates significant merit as the first prospective cohort study in Asia to compare different standardization approaches for HGS in predicting subsequent functional decline, providing critical insights for sarcopenia diagnosis, suggesting that MSS may warrant prioritization over absolute strength measurements.

In conclusion, this study highlights MSS: grip strength normalized to dominant hand muscle mass: as a sensitive and effective marker of impaired physical performance. MSS outperformed conventional measures and showed a stronger link to impaired function than HGS‐ and MQI‐defined sarcopenia. Its association with unfavourable cardiometabolic and inflammatory profiles supports MSS as a biologically plausible indicator of muscle health. Given its simplicity and predictive value, MSS may be a useful tool for early detection and monitoring of muscle health in ageing.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Table S1: Details of measurement devices for serum biomarkers.

Table S2: Baseline characteristics of participants stratified by sarcopenia defined by muscle specific strength, grip strength and muscle quality index.

Table S3: Associations of muscle‐specific strength, grip strength, muscle quality index, and sarcopenia with impaired physical performance.

Table S4: Muscle‐specific strength and impaired physical performance stratified by age, sex and chronic conditions.

Table S5: Baseline biomarker profile stratified by muscle specific strength.

Table S6: Multinomial logistic regressions explore associations between muscle‐specific strength and biomarkers.

Figure S1: Sensitivity analysis using inverse probability weighting to account for missing follow‐up data.

Figure S2: Associations of MSS, sarcopenic obesity, and MSS‐sarcopenic obesity with impaired physical performance.

Supplement file at the original source: open the original paper. This file is not included in this text import.

Acknowledgements

We would like to thank the Interdisciplinary Research Center for Healthy Longevity of National Yang Ming Chiao Tung University from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan for supporting the research work. We express our gratitude for the support from the Center for Geriatrics and Gerontology of Taipei Veterans General Hospital and the Department of Family Medicine of Taipei Veterans General Hospital Yuanshan Branch.

References

1 L.‐N. Peng , D. Chan , D. Han , et al., “Advancing Sarcopenia Diagnosis and Treatment: Recommendations From the Taiwan Advisory Panel for Sarcopenia ,” Aging Medicine and Healthcare 15 (2024 ): 8Not reported14 .
2 C. K. Liang , L. N. Peng , M. H. Lin , et al., “Long‐Term Mortality Risk in Older Adults With Sarcopenia: An 11‐Year Prospective Cohort Study Comparing AWGS 2014 and AWGS 2019 Guidelines for Enhanced Clinical Utility and Accurate Risk Prediction ,” Journal of Nutrition, Health & Aging 27 (2023 ): 507Not reported513 . 10.1007/s12603-023-1940-y 37498098
3 S. E. Weng , Y. W. Huang , Y. C. Tseng , et al., “The Evolving Landscape of Sarcopenia in Asia: A Systematic Review and Meta‐Analysis Following the 2019 Asian Working Group for Sarcopenia (AWGS) Diagnostic Criteria ,” Archives of Gerontology and Geriatrics 128 (2025 ): 105596. 39232423 10.1016/j.archger.2024.105596
4 A. J. Cruz‐Jentoft , G. Bahat , J. Bauer , et al., “Sarcopenia: Revised European Consensus on Definition and Diagnosis ,” Age and Ageing 48 (2019 ): 16Not reported31 . 30312372 10.1093/ageing/afy169 PMC6322506
5 L. K. Chen , J. Woo , P. Assantachai , et al., “Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment ,” Journal of the American Medical Directors Association 21 (2020 ): 300Not reported307.e2 . 32033882 10.1016/j.jamda.2019.12.012
6 B. Kirk , P. M. Cawthon , H. Arai , et al., “The Conceptual Definition of Sarcopenia: Delphi Consensus From the Global Leadership Initiative in Sarcopenia (GLIS) ,” Age and Ageing 53 (2024 ): afae052. 38520141 10.1093/ageing/afae052 PMC10960072
7 A. Mehra , R. L. Snarr , K. S. Park , J. L. Krok‐Schoen , S. A. Czerwinski , and B. S. Nickerson , “Muscle Quality Index Comparisons Between Hispanics and Non‐Hispanic Caucasians Using Dual Energy X‐Ray Absorptiometry and Handgrip Strength ,” European Journal of Clinical Nutrition 78 (2024 ): 1064Not reported1071 . 39117905 10.1038/s41430-024-01484-y PMC11611728
8 J. P. D. Costa Pereira , C. M. Prado , M. C. Gonzalez , et al., “Strength‐to‐Muscle Radiodensity: A Potential New Index for Muscle Quality ,” Clinical Nutrition 43 (2024 ): 1667Not reported1674 . 38815492 10.1016/j.clnu.2024.05.032
9 S. Barbat‐Artigas , S. Plouffe , C. H. Pion , and M. Aubertin‐Leheudre , “Toward a Sex‐Specific Relationship Between Muscle Strength and Appendicular Lean Body Mass Index? ,” Journal of Cachexia, Sarcopenia and Muscle 4 (2013 ): 137Not reported144 . 23389764 10.1007/s13539-012-0100-8 PMC3684704
10 W. J. Lee , L. N. Peng , M. H. Lin , C. H. Loh , F. Y. Hsiao , and L. K. Chen , “Intrinsic Capacity Differs From Functional Ability in Predicting 10‐Year Mortality and Biological Features in Healthy Aging: Results From the I‐Lan Longitudinal Aging Study ,” Aging (Albany NY) 15 (2023 ): 748Not reported764 . 36750172 10.18632/aging.204508 PMC9970311
11 Y. H. Lee , W. J. Lee , L. N. Peng , M. H. Lin , F. Y. Hsiao , and L. K. Chen , “Cardiovascular Disease Risk Burden, Cognitive Impairments and Incident Dementia Among Community‐Dwelling Middle‐Aged and Older Adults: An 8‐Year Longitudinal Follow‐Up Study ,” Journal of Nutrition, Health & Aging 27 (2023 ): 641Not reported648 . 10.1007/s12603-023-1954-5 37702337
12 L. Y. Tseng , C. K. Liang , L. N. Peng , et al., “The Distinct Impacts of Sarcopenic and Dynapenic Obesity on Mortality in Middle‐Aged and Older Adults Based on Different Adiposity Metrics: Results From I‐Lan Longitudinal Aging Study ,” Clinical Nutrition 43 (2024 ): 1892Not reported1899 . 38991414 10.1016/j.clnu.2024.06.035
13 E. von Elm , D. G. Altman , M. Egger , S. J. Pocock , P. C. Gøtzsche , and J. P. Vandenbroucke , “The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies ,” Journal of Clinical Epidemiology 61 (2008 ): 344Not reported349 . 18313558 10.1016/j.jclinepi.2007.11.008
14 B. C. Clark , “Neural Mechanisms of Age‐Related Loss of Muscle Performance and Physical Function ,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 78 (2023 ): 8Not reported13 . 36738253 10.1093/gerona/glad029 PMC10272985
15 B. Vellas , H. Villars , G. Abellan , et al., “Overview of the MNA: Its History and Challenges ,” Journal of Nutrition, Health & Aging 10 (2006 ): 456Not reported463 discussion 63‐5. 17183418
16 P. M. Lewinsohn , J. R. Seeley , R. E. Roberts , and N. B. Allen , “Center for Epidemiologic Studies Depression Scale (CES‐D) as a Screening Instrument for Depression Among Community‐Residing Older Adults ,” Psychology and Aging 12 (1997 ): 277Not reported287 . 9189988 10.1037//0882-7974.12.2.277
17 N. W. Guo , H. C. Liu , P. F. Wong , et al., “Chinese Version and Norms of the Mini‐Mental State Examination ,” Taiwan Academy of Physical Medicine and Rehabilitation 16 (1988 ): 52Not reported59 .
18 R. Hebert , R. Carrier , and A. Bilodeau , “The Functional Autonomy Measurement System (SMAF): Description and Validation of an Instrument for the Measurement of Handicaps ,” Age and Ageing 17 (1988 ): 293Not reported302 . 2976575 10.1093/ageing/17.5.293
19 M. Charlson , T. P. Szatrowski , J. Peterson , and J. Gold , “Validation of a Combined Comorbidity Index ,” Journal of Clinical Epidemiology 47 (1994 ): 1245Not reported1251 . 7722560 10.1016/0895-4356(94)90129-5
20 Y. Ichikawa , Y. Watanabe , K. Irie , et al., “Decreased Homeostasis Model Assessment of β‐Cell Function in Patients Without Diabetes Can Predict Future Events in Patients With Cardiovascular Disease ,” Circulation Journal 89 (2025 ): 347Not reported353 . 39880644 10.1253/circj.CJ-24-0773
21 S. P. Rose , A. Srinivas , A. Prashant , P. Periera , S. M. Nataraj , and K. K. Shivashankar , “Inflammation, Muscle Health and Aging: Calf Circumference as a Cost‐Effective Diagnostic Indicator of Sarcopenia ,” Archives of Gerontology and Geriatrics Plus 1 , no. 3 (2024 ): 100046.
22 K. Keller and M. Engelhardt , “Strength and Muscle Mass Loss With Aging Process. Age and Strength Loss ,” Muscles, Ligaments and Tendons Journal 3 (2013 ): 346Not reported350 . 24596700 PMC3940510
23 L. K. Chen , L. C. Meng , L. N. Peng , et al., “Mapping Normative Muscle Health Metrics Across the Aging Continuum: A Multinational Study Pooling Data From Eight Cohorts in Japan, Malaysia and Taiwan ,” Journal of Cachexia, Sarcopenia and Muscle 16 (2025 ): e13731. 39971708 10.1002/jcsm.13731 PMC11839280
24 S. von Haehling , J. E. Morley , and S. D. Anker , “An Overview of Sarcopenia: Facts and Numbers on Prevalence and Clinical Impact ,” Journal of Cachexia, Sarcopenia and Muscle 1 (2010 ): 129Not reported133 . 21475695 10.1007/s13539-010-0014-2 PMC3060646
25 K. M. Haizlip , B. C. Harrison , and L. A. Leinwand , “Sex‐Based Differences in Skeletal Muscle Kinetics and Fiber‐Type Composition ,” Physiology (Bethesda) 30 (2015 ): 30Not reported39 . 25559153 10.1152/physiol.00024.2014 PMC4285578
26 L. N. Peng , W. J. Lee , L. K. Liu , M. H. Lin , and L. K. Chen , “Healthy Community‐Living Older Men Differ From Women in Associations Between Myostatin Levels and Skeletal Muscle Mass ,” Journal of Cachexia, Sarcopenia and Muscle 9 (2018 ): 635Not reported642 . 29654636 10.1002/jcsm.12302 PMC6104118
27 K. Beaudry and M. de Lisio , “Sex‐Based Differences in Muscle Stem Cell Regulation Following Exercise ,” Exercise and Sport Sciences Reviews 52 (2024 ): 87Not reported94 . 38445901 10.1249/JES.0000000000000337
28 W. J. Lee , L. N. Peng , S. T. Chiou , and L. K. Chen , “Relative Handgrip Strength Is a Simple Indicator of Cardiometabolic Risk Among Middle‐Aged and Older People: A Nationwide Population‐Based Study in Taiwan ,” PLoS ONE 11 (2016 ): e0160876. 27559733 10.1371/journal.pone.0160876 PMC4999244
29 Y. L. Huang , W. J. Chang , C. H. Huang , et al., “Proteo‐Metabolomic Insights for Early Dual Physical and Cognitive Impairments: A Search for Biomarkers of Healthy Aging Based on Muscle‐Brain Crosstalk ,” Aging Cell 24 (2025 ): e14407. 39517120 10.1111/acel.14407 PMC11896308
30 D. Horáková , L. Štěpánek , L. Štěpánek , et al., “What Are the Real Associations of Homeostasis Model Assessment (HOMA) With Body Mass Index and Age? ,” Endokrynologia Polska 73 (2022 ): 736Not reported742 . 36059166 10.5603/EP.a2022.0031
31 L. Ferrucci and E. Fabbri , “Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty ,” Nature Reviews. Cardiology 15 (2018 ): 505Not reported522 . 30065258 10.1038/s41569-018-0064-2 PMC6146930
32 S. F. Khalil , M. S. Mohktar , and F. Ibrahim , “The Theory and Fundamentals of Bioimpedance Analysis in Clinical Status Monitoring and Diagnosis of Diseases ,” Sensors (Basel) 14 (2014 ): 10895Not reported10928 . 24949644 10.3390/s140610895 PMC4118362
33 C. Castillo Castro , R. González Arellanes , C. G. Camacho Mondragón , et al., “Agreement Between Bioelectrical Impedance Analysis and Dual‐Energy X‐Ray Absorptiometry to Estimate Fat Mass in Hispanic Adults With Type 2 Diabetes Mellitus: A Cross‐Sectional Study ,” Clinical Medicine Insights: Endocrinology Diabetes 17 (2024 ): 11795514241274691. 39224772 10.1177/11795514241274691 PMC11367586
Publication and source details

Original title: Muscle‐Specific Strength Better Predicts Physical Performance Decline Than Conventional Metrics: The I‐Lan Longitudinal Aging Study

Wen‐Kai Chien; Wei‐Ju Lee; Chih‐Kuang Liang; Ko‐Han Yen; Li‐Ning Peng; Ming‐Hsien Lin; Ching‐Hui Loh; Fei‐Yuan Hsiao; Liang‐Kung Chen

Journal of Cachexia, Sarcopenia and Muscle · 2025

* Correspondence:
Wei‐Ju Lee (leewju@gmail.com)
Liang‐Kung Chen (lkchen2@vghtpe.gov.tw)
© 2025 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. National Science and Technology Council10.13039/501100020950 NSTC‐113‐2314‐B‐A49‐060NSTC 114‐2314‐B‐A49‐042 Taipei Veterans General Hospital10.13039/501100011912 114 VACS‐001

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:41:01.780422+00:00

DOI: 10.1002/jcsm.70078 · PMC12485295